Amrein, Mathias W.,Gunasekara, Lasantha C.,Pratt, Ryan
申请号：
AU2012390966
公开号：
AU2012390966B2
申请日:
2012.09.27
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The use of cholesterol-sequestering agents, such as methyl-beta-cyclodextrin, for the treatment of pulmonary surfactant dysfunction is disclosed. It was discovered that oxidative damage to pulmonary surfactant arises due to the interaction between reactive oxygen species and cholesterol. Thus, by removing cholesterol from pulmonary7 surfactant through the addition of a cholesterol-sequestering agent, oxidative damage to the surfactant is mitigated. It was also shown that methyl-beta-cyclodextrin can restore normal function to dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non cystic fibrosis bronchiolitis.
